Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says | Fierce Pharma
Novartis sidesteps Europe travel ban to provide CAR-T drug Kymriah to patients | Fierce Pharma
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
The Process of CAR-T Cell Therapy | Novartis
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah | Fierce Pharma
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
ASCO: Positive trial shows Novartis' Kymriah poised to play catch-up in CAR- T rivalry with Gilead's Yescarta | Fierce Pharma
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Frontiers | Manufacturing and Management of CAR T-Cell Therapy in “COVID-19's Time”: Central Versus Point of Care Proposals
